Abstract：Objective To initially investigate whether simultaneous radiochemotherapy with hyperthermia can prolong the survival of glioblastoma (GBM) patients. Methods Clinical data of 61 GBM patients undergoing surgery in our hospital from September 2016 to June 2019 were retrospectively analyzed. According to different treatment methods, all patients were divided into the control group (n=34) and observation group (n=27). In the control group, three-dimensional radiotherapy with a dose of 60Gy combined with temoazolamine chemotherapy was delivered. In the observation group, simultaneous radiochemotherapy with 15-20 cycles of hyperthermia at 40-41℃ was supplemented. The survival time was calculated by Kaplan-Meier method, and the survival time was compared with log-rank test between two groups. Results The median progression-free survival in the observation group was significantly longer than that in the control group (14.33 months vs.9.94 months, P<0.05). The median overall survival in the observation group was also remarkably higher than that in the control group (18 months vs. 14 months, P<0.05). Conclusions Simultaneous radiochemotherapy with hyperthermia is innovatively applied to treat GBM after surgical resection. Preliminary findings demonstrate that compared with chemoradiotherapy, simultaneous radiochemotherapy with hyperthermia can prolong the survival time of GBM patients.
Zhao Jingyi,Li Bingyan,Chen Linhui et al. Preliminary survival analysis of postoperative simultaneous radiochemotherapy with hyperthermia in glioblastoma patients[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 888-891.
[1] Pranckeviciene A, Bunevicius A.Depression screening in patients with brain tumors:a review[J]. CNS Oncol, 2015, 4(2):71-78.DOI:10.2217/cns.14.60. [2] Delgado-López PD, Corrales-García EM.Survival in glioblastoma:a review on the impact of treatment modalities[J]. Clin Transl Oncol, 2016, 18(11):1062-1071.DOI:10.1007/s12094-016-1497-x. [3] Ohgaki H, Kleihues P.Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas[J]. J Neuropathol Exp Neurol, 2005, 64(6):479-489.DOI:10.1093/jnen/64.6.479. [4] Ganipineni LP, Danhier F, Préat V.Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment[J]. J Control Release, 2018, 281(1):4 2-57.DOI:10.1016/j.jconrel.2018.05.008. [5] 于金明,王仁本,王蔚林.肿瘤热疗的热剂量学研究进展与评价[J]. 中华肿瘤杂志,2004, 26(05):257-259.DOI:10.3760/j.issn:0253-3766.2004.05.001. Yu JM, Wang RB, Wang WL.Progress and evaluation ofthermodositics of tumor heat therapy[J]. Chin J Oncol, 2004, 26(05):257-259.DOI:10.3760/j.issn:0253-3766.2004.05.001. [6] Wen PY, Kesari S.Malignant gliomas in adults[J]. N Engl J Med, 2008, 359(5):492-507.DOI:10.1056/NEJMra0708126. [7] Lacroix M, Abi-Said D, Fourney DR, et al.A multivariate analysis of 416 patients with glioblastoma multiforme:prognosis, extent of resection, and survival[J]. J Neurosurg, 2001, 95(2):190-198.DOI:10.3171/jns.2001.95.2.0190. [8] Stupp R, Mason WP, van den Bent MJ, et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996.DOI:10.1056/NEJMoa043330. [9] Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, et al.Bevacizumab in high-grade gliomas:a review of its uses, toxicity assessment, and future treatment challenges[J]. Onco Targets Ther, 2013, 6(20):371-389.DOI:10.2147/OTT.S38628. [10] Wilson TA, Karajannis MA, Harter DH.Glioblastoma multiforme:State of the art and future therapeutics[J]. Surg Neurol Int, 2014, 5(1):64.DOI:10.4103/2152-7806.132138. [11] Urbańska K, Sokoowska J, Szmidt M, et al.Glioblastoma multiforme-an overview[J]. Contemp Oncol (Pozn), 2014, 18(5):307-312.DOI:10.5114/wo.2014.40559. [12] Karabeber H, Huang R, Iacono P, et al.Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner[J]. ACS Nano, 2014, 8(10):9755-9766.DOI:10.1021/nn503948b. [13] Huang R, Harmsen S, SamⅡ JM, et al.High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe[J]. Theranostics, 2016,6(8):1075-1084.DOI:10.7150/thno.13842. [14] Hambardzumyan D, Becher OJ, Rosenblum MK, et al.PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo[J]. Genes Dev, 2008, 22(4):436-448.DOI:10.1101/gad.1627008. [15] 黄明火,张正洪.局部热疗联合手术治疗对脑胶质瘤的效果观察[J]. 广东医学,2015, 36(23):3654-3656. Huang MH, Zhang ZH.Observation on the effect of local thermotherapy on glioma[J]. Guangdong Med J, 2015, 36(23):3654-3656. [16] 孙承龙,俞文华,王昊,等.射频热疗联合替莫唑胺在高级别脑胶质瘤患者术后治疗中的效果[J]. 中国乡村医药,2017, 24(18):8-9.DOI:10.3969/j.issn.1006-5180.2017.18.004. Sun CL, Yu WH, Wang H, et al.Effects of radiofrequency thermotherapy combined with timozolamine in postoperative treatment in patients with high-grade glioma[J]. Chin J Rural Med Pharm, 2017, 24(18):8-9.DOI:10.3969/j.issn.1006-5180.2017.18.004. [17] 陈洪雷,张苗,王雅杰.热疗的放射增敏作用及生物学机理研究进展[J]. 中华放射医学与防护杂志,2004, 24(5):481-483.DOI:10.3760/cma.j.issn.0254-5098.2004.05.043. Chen HL, Zhang M, Wang YJ.Research progress inradiation sensitization and biological mechanism of heattherapy[J]. Chin J Radiol Med Protect, 2004, 24(5):481-483.DOI:10.3760/cma.j.issn.0254-5098.2004.05.043. [18] Mackey MA, Ianzini F.Enhancement of radiation-induced mitotic catastrophe by moderate hyperthermia[J]. Int J Radiat Biol, 2000, 76(2):273-280.DOI:10.1080/095530000138925. [19] 宋凯镔,王文波,李雪松.肿瘤热疗机制的研究进展[J]. 中国肿瘤,2009, 18(1):50-53. Song KB, Wang WB, Li XS.Research progress in thermotherapic mechanism for cancer[J]. Chin Cancer, 2009, 18(1):50-53. [20] 秦丽娟,张军伟,张田,等.热疗联合人肿瘤坏死因子对TNFR1高表达胶质瘤的细胞周期、F-肌动蛋白及其侵袭性的影响[J]. 肿瘤防治研究,2013, 40(6):551-554.DOI:10.3971/j.issn.1000-8578.2013.06.011. Qin LJ, Zhang JW, Zhang T, et al.Effects of thermotherapy combined with human tumor necrosis factor on the cell cycle, F-actin and its aggression of TNFR1 high-expressed glioma[J]. Cancer Res Prevent Treat, 2013, 40(6):551-554.DOI:10.3971/j.issn.1000-8578.2013.06.011.
2021, Vol. 30 
